Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 14/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236041 | 0.83 | AKR1B1 (0.69) | AKR1B1 | |
| SCHEMBL6240241 | 0.80 | AKR1B1 (0.58) | AKR1B1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29594234 | 0.70 | IDO1 (0.57) | HSD17B10ADRA1ATAAR1IDO1 | |
| SCHEMBL6207869 | 0.70 | AKR1B1 (1.00) | AKR1B1LMNAPOLB | |
| SCHEMBL8480289 | 0.69 | LMNA (0.60) | AKR1B1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6237022 | 0.69 | AKR1B1 (0.76) | AKR1B1 | |
| SCHEMBL6239197 | 0.68 | AKR1B1 (0.62) | AKR1B1 | |
| SCHEMBL6238212 | 0.68 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL6241896 | 0.68 | AKR1B1 (1.00) | AKR1B1 | |
| SCHEMBL6234479 | 0.67 | AKR1B1 (0.78) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236720-B1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6730674-B2 | ANTIDIABETIC AGENTS | PFIZER INC | 2004-05-04 | — | — | US | disclosed |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | MARTIN WILLIAM H (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1236720-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | ALDOA, PDXK, AKR1B1 | AKR1B1 3/4885PDE4A 1617/4885PDE4B 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.